Physician
Infectious Disease
Dr. George Sakoulas, MD
|
|
Give Review
George Sakoulas, MD practices Infectious Disease. He researched medicine at Harvard Medical School. Harvard Medical School is one of the top medical schools in the US. Harvard Medical School has a rank of 1 in research and a 12 in primary care George Sakoulas is a published doctor and has 102 publications published. The lastest was: 'Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: res...' George Sakoulas accepts all Medicare patients.
Publications
- Penicillin binding protein 1 is important in the compensatory response of Staphylococcus aureus to daptomycin-induced membrane damage and is a potential target for β-l...
- When sepsis persists: a review of MRSA bacteraemia salvage therapy.
- Examining the Use of Ceftaroline in the Treatment of Streptococcus pneumoniae Meningitis with Reference to Human Cathelicidin LL-37.
- Heterogeneity of genetic pathways toward daptomycin nonsusceptibility in Staphylococcus aureus determined by adjunctive antibiotics.
- β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium.
- Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia.
- Avoiding the Perfect Storm: The Biologic and Clinical Case for Reevaluating the 7-Day Expectation for Methicillin-Resistant Staphylococcus aureus Bacteremia Before Swi...
- Reply to Eschenauer et al.
- Daptomycin in Combination With Other Antibiotics for the Treatment of Complicated Methicillin-Resistant Staphylococcus aureus Bacteremia.
- Heterogeneity of mprF Sequences in Methicillin-Resistant Staphylococcus aureus Clinical Isolates: Role in Cross-Resistance between Daptomycin and Host Defense Antimicr...
- Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE.
- Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes.
- Antimicrobial Salvage Therapy for Persistent Staphylococcal Bacteremia Using Daptomycin Plus Ceftaroline.
- Defining Daptomycin Resistance Prevention Exposures in Vancomycin Resistant Enterococcus (VRE) faecium and E. faecalis.
- Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated en...
- Efficacy and Safety of Daptomycin in Patients with Renal Impairment: A Multicenter Retrospective Analysis.
- Human Cathelicidin LL-37 Resistance and Increased Daptomycin MIC in USA 600 (ST45) Methicillin-resistant Staphylococcus aureus is Associated with Increased Mortality i...
- Ceftaroline Restores Daptomycin Activity Against Daptomycin Nonsusceptible Vancomycin Resistant Enterococcus faecium.
- Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus.
- A Current Perspective on Daptomycin for the Clinical Microbiologist.
- Multicenter study of high-dose daptomycin for treatment of enterococcal infections.
- A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis.
- Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus.
- β-lactam Antibiotics Targeting PBP1 Selectively Enhance Daptomycin Activity against Methicillin-Resistant Staphylococcus aureus.
- Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.
- Multicenter Evaluation of the Clinical Outcomes of Daptomycin with and without Concomitant ?-Lactams in Patients with Staphylococcus aureus Bacteremia and Mild to Mode...
- Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pha...
- Elevated serum interleukin-10 at time of hospital admission is predictive of mortality in patients with Staphylococcus aureus bacteremia.
- Genotypic and Phenotypic Evaluation of the evolution of high-level daptomycin non-susceptibility in vancomycin-resistant Enterococcus faecium.
- Reduced Susceptibility to Host Defense Cationic Peptides and Daptomycin Co-Emerge in MRSA from Daptomycin-Naive Bacteremic Patients.
- Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates (''the MIC Creep''): implications for therapy.
- Novel bacterial metabolite merochlorin A demonstrates in vitro activity against multi-drug resistant methicillin-resistant Staphylococcus aureus.
- Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium.
- Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia.
- Concentration-dependent effects of antimicrobials on Staphylococcus aureus toxin-mediated cytokine production from peripheral blood mononuclear cells.
- High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study.
- Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.
- Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of...
- Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach.
- Increased mortality with accessory gene regulator (agr) dysfunction in Staphylococcus aureus among bacteremic patients.
- Treatment of meningitis caused by vancomycin-resistant Enterococcus faecium: high-dose and combination daptomycin therapy.
- Combinatorial phenotypic signatures distinguish persistent from resolving methicillin-resistant Staphylococcus aureus bacteremia isolates.
- Empiric antibiotic therapy for Staphylococcus aureus bacteremia may not reduce in-hospital mortality: a retrospective cohort study.
- Factors influencing time to vancomycin-induced clearance of nonendocarditis methicillin-resistant Staphylococcus aureus bacteremia: role of platelet microbicidal prote...
- Relationship between population density of attorneys and prevalence of methicillin-resistant Staphylococcus aureus: is medical-legal pressure on physicians a driving f...
- Polyphyletic emergence of linezolid-resistant staphylococci in the United States.
- Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus.
- Clinical outcomes with daptomycin: a post-marketing, real-world evaluation.
- Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a r...
- Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions.
- Reduced biofilm production associated with increasing linezolid MICs among linezolid-resistant staphylococci.
- Evaluating aztreonam and ceftazidime pharmacodynamics with Escherichia coli in combination with daptomycin, linezolid, or vancomycin in an in vitro pharmacodynamic model.
- Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing ...
- Accessory gene regulator dysfunction: an advantage for Staphylococcus aureus in health-care settings?
- Loss of vancomycin bactericidal activity against accessory gene regulator (agr) dysfunctional Staphylococcus aureus under conditions of high bacterial density.
- Genotypic and phenotypic relationships among methicillin-resistant Staphylococcus aureus from three multicentre bacteraemia studies.
- Daptomycin for soft tissue infection and neutropenia in a myelogenous leukemia patient who failed prior vancomycin therapy.
- Vancomycin ototoxicity: a reevaluation in an era of increasing doses.
- Cryptococcal infection presenting as cellulitis in a renal transplant recipient.
- Clinical rationale for treatment of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin.
- Microbiological and genotypic analysis of methicillin-resistant Staphylococcus aureus bacteremia.
- Associations between the genotypes of Staphylococcus aureus bloodstream isolates and clinical characteristics and outcomes of bacteremic patients.
- Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.
- Relationship of linezolid minimum inhibitory concentration and time to bacterial eradication in treatment for methicillin-resistant Staphylococcus aureus infection.
- Teicoplanin pharmacodynamics in reference to the accessory gene regulator (agr) in Staphylococcus aureus using an in vitro pharmacodynamic model.
- Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
- Clinical update on the diagnosis and treatment of bacterial endocarditis.
- Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin.
- daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
- Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, a...
- Daptomycin in the treatment of bacteremia.
- Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus.
- Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia.
- Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and function.
- Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF.
- Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus.
- Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin.
- Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia.
- Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy.
- Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulato...
- Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-ind...
- Effects of glucose on fsr-mediated biofilm formation in Enterococcus faecalis.
- Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy.
- Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA.
- Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.
- Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin.
- Hematogenous enterococcal vertebral osteomyelitis: report of 2 cases and review of the literature.
- Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia.
- Introduction of erm(C) into a linezolid- and methicillin-resistant Staphylococcus aureus does not restore linezolid susceptibility.
- Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.
- Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance?
- Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis.
- Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype.
- Prevalence of the fsr locus in Enterococcus faecalis infections.
- Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin.
- Methicillin-resistant Staphylococcus aureus: comparison of susceptibility testing methods and analysis of mecA-positive susceptible strains.
- BK-related polyomavirus vasculopathy in a renal-transplant recipient.
- Linezolid resistance in a clinical isolate of Staphylococcus aureus.
- Brainstem and striatal encephalitis complicating Mycoplasma pneumoniae pneumonia: possible benefit of intravenous immunoglobulin.
- Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: res...
- Standard susceptibility testing overlooks potent azithromycin activity and cationic peptide synergy against MDR Stenotrophomonas maltophilia.
Schools
Harvard Medical School
Beth Israel Deaconess Med Center
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
Education
-
Beth Israel Deaconess Medical Center -
Harvard Medical School
Drug Facts
| NPI NUMBER | 1184647893 | |
| NPPES Provider LastName | SAKOULAS | |
| NPPES Provider FirstName | GEORGE | |
| NPPES Provider ZIPCode | 921012303 | |
| NPPES Provider State | CA | |
| Specialty Description | Infectious Disease | |
| Total Claim Count | 142.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1184647893 |
| Last Name Of The Provider | SAKOULAS |
| First Name Of The Provider | GEORGE |
| View All |
Similar Doctors
|
|
Dr. Robert T. Schooley, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeanne M. Cabeza, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ryan Maves, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vi Q. Bowman, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Nancy F. Crum Cianflone, MD |
|
|
Dr. Mary F. Bavaro, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Samuel A. Bozzette, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harold L. Groff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert V. Barthel, MD |
|
|
Dr. Cathy L. Logan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kalpana Natrajan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David T. Pride, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael N. Oxman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elaine F. Pierce, MD
This Doctor is OpenDoctor Recommended.
|